Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
GAD-alum given into lymph nodes to type 1 diabetes patients participating in an open-label pilot trial resulted in preservation of C-peptide similar to promising results from other trials. Here, we compared the immunomodulatory effect of giving GAD-alum directly into lymph nodes versus that induced...
Saved in:
Main Authors: | Beatriz Tavira, Hugo Barcenilla, Jeannette Wahlberg, Peter Achenbach, Johnny Ludvigsson, Rosaura Casas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2018/9391845 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhanced Electrochemiluminescence from Ruthenium-Tagged Immune Complex at Flexible Chains for Sensitive Analysis of Glutamate Decarboxylase Antibody
by: Yuyao Zhang, et al.
Published: (2025-01-01) -
Probable Anti-Glutamate Decarboxylase 65 (Gad65) Antibody-Associated Cerebellar Ataxia. Clinical Case Report and Literature Review
by: J. Valinčiūtė, et al.
Published: (2023-11-01) -
Clinical and Experimental Immunomodulation
by: Lenin Pavón, et al.
Published: (2013-01-01) -
Clinical and Experimental Immunomodulation 2014
by: Lenin Pavón, et al.
Published: (2015-01-01) -
Clinical and Experimental Immunomodulation 2016
by: Lenin Pavón, et al.
Published: (2017-01-01)